Sotera Health (SHC)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$16.39+2.25%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
QuarterlyIQ Insights · SHC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 6.4% |
| Our one-year growth estimate | diamond | 5.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 0.4 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 12 industry peers · Company calendar date is not available
SHC — director transition
Dated 2026-08-14
Director — James C. Neary: A Class I director resigned effective shortly after notification with no stated disagreement, representing a standard board turnover event rather than an executive crisis.
Why it matters: SHC reached its long-term net leverage target range in June. Further debt reduction would add room for future spending and growth.
Supportive ifA later quarterly report shows net leverage below 3.0x.
Worry ifA later quarterly report shows net leverage above 3.0x.
Why it matters: The 2026 capital spending range rose from its prior low end. Spending above the new range could weaken cash available for debt reduction.
Worry ifFull-year 2026 capital spending tops $225 million.
Less concerning ifFull-year 2026 capital spending is at or below $225 million.
Why it matters: Nordion's strong first-half growth came in part from cobalt-60 harvest timing. The next results can show if growth continues after that boost.
Watch forQ3 Nordion constant-currency revenue grows year over year. Harvest timing does not drive most of the volume and mix.
Also watch forQ3 Nordion revenue falls year over year in constant currency. Harvest timing lowers volume and mix.
Why it matters: SHC raised its 2026 revenue and EBITDA outlook after strong first-half results. Q3 results will show whether growth stays on track.
Watch forQ3 constant-currency revenue grows at least 5.25%, and adjusted EBITDA grows at least 5.75%. SHC keeps its raised outlook.
Also watch forQ3 constant-currency revenue growth is below 5.25%, or adjusted EBITDA growth is below 5.75%. SHC cuts its 2026 outlook.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$108 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $279 loss on $10,000 · 2.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,214 loss on $10,000 · 32.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Nelson Labs had weak first-half constant-currency revenue growth, and its first-half segment income fell. A recovery would ease pressure from this business.
Watch forQ3 Nelson Labs constant-currency revenue and segment income both grow year over year.
Also watch forQ3 Nelson Labs constant-currency revenue or segment income falls year over year.